CTS received notification from Sanochemia Pharmazeutika AG of their intent to immediately discontinue production of Fluorognost HIV-1 IFA test kits routinely used for confirmation of HIV-1 antibody-reactive donations. Based on our current testing volume, CTS has sufficient HIV-1 IFA reagent inventory to continue performing this confirmatory test through the end of August 2019.
Check out the Communication page for the complete details on the updated IFA HIV-1 assay or by clicking the link: Communications
Reminder - The CTS Reentry form, CTS-00172, will be updated on Monday July 2, 2018. It's posted ...
After a recent reevaluation of the Monolisa anti-HBs EIA package insert, the CTS QA/Scientific team ...
We are very excited to launch our new website! Please take a few moments to click around and explore...
Josh Moon has been appointed Chief Operating Officer (COO) at Creative Testing Solutions (CTS), effe...
On December 28, 2021, the FDA updated the emergency use authorization (EUA) for COVID-19 conva...
The Q & A document from the Reentry Changes Webinar hosted on 06/06/18 has been posted in the Wh...